dihexa human clinical trials 2026 International Day 2026: inside First-in-Human trials Dihexa in Clinical Trials: What

Increasing evidence suggests that soluble A oligomers, rather than insoluble plaques, are major contributors to synaptic dysfunction and cognitive decline in AD, although their precise pathogenic role remains under active investigation and debate (Selkoe, 2008

Mercuric chloride (1 mg/kg i.v.) or cysplatinum (10 mg/kg s.c.) administration produces acute renal failure in experimental animals

The Clock Starts Ticking: Why Reconstitution Matters First, let's quickly touch on why peptides like BPC-157 arrive in a powdered, or lyophilized, state

Both in vitro and in vivo research involving rat tendons has shown that BPC-157 promotes collateralization and boosts fibroblast density in the setting of tendon, ligament, and bone injury